Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

Sandile Cele; Laurelle Jackson; David S. Khoury; Khadija Khan; Thandeka Moyo-Gwete; Houriiyah Tegally; James Emmanuel San; Deborah Cromer; Cathrine Scheepers; Daniel G. Amoako; Farina Karim; Mallory Bernstein; Gila Lustig; Derseree Archary; Muneerah Smith; Yashica Ganga; Zesuliwe Jule; Kajal Reedoy; Shi-Hsia Hwa; Jennifer Giandhari; Jonathan M. Blackburn; Bernadett I. Gosnell; Salim S. Abdool Karim; Willem A. Hanekom; Mary‐Ann Davies; Marvin Hsiao; Darren P. Martin; Koleka Mlisana; Constantinos Kurt Wibmer; Carolyn Williamson; Denis York; Rohen Harrichandparsad; Kobus Herbst; Prakash Jeena; Thandeka Khoza; Henrik N. Kløverpris; Alasdair Leslie; Rajhmun Madansein; Nombulelo Magula; Nithendra Manickchund; Mohlopheni J. Marakalala; Matilda Mazibuko; Mosa Moshabela; Ntombifuthi Mthabela; Kimesh Naidoo; Zaza M. Ndhlovu; Thumbi Ndung’u; Nokuthula Ngcobo; Kennedy Nyamande; Vinod Patel; Theresa Smit; Adrie J. C. Steyn; Emily Wong; Anne von Gottberg; Jinal N. Bhiman; Richard Lessells; Mahomed‐Yunus S. Moosa; Miles P. Davenport; Túlio de Oliveira; Penny L. Moore; Alex Sigal

doi:10.1038/s41586-021-04387-1

Keywords

NeutralizationChemistryComputational biologyComputer scienceVirologyBiologyVirus

Affiliated Institutions

Related Publications

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Yunlong Cao , Jing Wang , Fanchong Jian +27 more

Abstract The SARS-CoV-2 B.1.1.529 (Omicron) variant contains 15 mutations of the receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies requires ...

2021 Nature 1997 citations

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh , Robert W. Frenck , Ann R. Falsey +22 more

The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data re...

2020 New England Journal of Medicine 2665 citations

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Fernando P. Polack , Stephen J. Thomas , Nicholas Kitchin +26 more

A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral...

2020 New England Journal of Medicine 14917 citations

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Jamie Lopez Bernal , Nick Andrews , Charlotte Gower +12 more

Abstract Objective To estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (includ...

2021 BMJ 1367 citations

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Delphine Planas , Nell Saunders , Piet Maes +29 more

2021 Nature 1568 citations

Publication Info

Year: 2021
Type: article
Volume: 602
Issue: 7898
Pages: 654-656
Citations: 1161
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1161

OpenAlex

Cite This

APA Style

                            
                                
                                    Sandile Cele, 
                                
                                    Laurelle Jackson, 
                                
                                    David S. Khoury
                                
                                et al.
                            
                            (2021). 
                            Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. 
                            Nature
                            , 602
                            (7898)
                            , 654-656.
                            https://doi.org/10.1038/s41586-021-04387-1
                        

Identifiers

DOI: 10.1038/s41586-021-04387-1